Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
PR Newswire

News of the day

Nventa to Present at Upcoming Investor Conferences

3rd September 2008 SAN DIEGO, September 3 /PRNewswire/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that the company will present corporate updates at a number of upcoming industry and financial conferences. Nventa's presentations will focus on HspE7, the company's lead product candidate for the treatment of human papillomavirus (HPV)-related diseases, as well as the company's proprietary Toll-like Receptor 3 (TLR3) agonist vaccine adjuvant program and additional corporate developments. ... more

Essilor's First-Half 2008 Results

28th August 2008 CHARENTON-LE-PONT, France, August 28 /PRNewswire/ -- The Board of Directors of Essilor International, the world leader in ophthalmic optics, has approved the financial statements for the six months ended June 30, 2008. (1) Adjusted for the two-for-one stock split on July 16, 2007 more

Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program

26th August 2008 ROCKVILLE, Maryland, August 26 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today favorable results from the second stage of the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate. The vaccine, which does not contain an adjuvant, induced robust neutralizing antibody responses. Novavax's VLP candidate is directed against the H5N1 A/Indonesia/05/2005 avian influenza strain. Avian influenza emerged in humans in Indonesia in 2005 and has... more
Conference Call Announcements RSS feed

PR Newswire search

Search the PR Newswire by keyword. Alternatively our advanced search allows you to query by category.
Category
To choose more then one item on the list hold CTRL button while selecting. To deselect items press CTRL button and deselect.

More recent news

Mymetics Corporation Important Shareholders Information Conference Call
25th August 2008 NYON, Switzerland, August 25 /PRNewswire/ -- Mymetics Corporation (OTC: MYMX), will be holding an important conference call on Wednesday August 27th 2008 at 1 PM New York Time to update all...

Rosetta Genomics Reports Second Quarter 2008 Financial Results
19th August 2008 REHOVOT, Israel and JERSEY CITY, New Jersey, August 19 /PRNewswire/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based diagnostic and therapeutic products, reported today...

Senetek PLC Reports Second Quarter 2008 Financial Results
14th August 2008 NAPA, California, August 14 /PRNewswire/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today...

Amsterdam Molecular Therapeutics Reports Half Year Results 2008
13th August 2008 AMSTERDAM, August 13 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2008.

Amsterdam Molecular Therapeutics Reports Half Year Results 2008
13th August 2008 AMSTERDAM, August 13 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2008.

AMT to Release Half Year 2008 Results on August 13, 2008
5th August 2008 AMSTERDAM, The Netherlands, August 5 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it will release its financial...

Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
31st July 2008 COPENHAGEN, July 31 /PRNewswire/ -- Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today positive top-line results from an interim analysis of the Phase III pivotal study...

Misys Announces Preliminary Results for the Year Ended 31 May 2008
24th July 2008 LONDON, July 24 /PRNewswire/ -- Key Highlights Misys plc (FTSE: MSY.L) delivers results ahead of expectations and is now raising targets for the next phase of the turnaround. Misys generated...

Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
4th July 2008 BASINGSTOKE, England and PHILADELPHIA, July 4 /PRNewswire/ -- Shire Limited (LSE:SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce second quarter 2008 earnings on...

Shire to Add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
3rd July 2008 BASINGSTOKE, England and CAMBRIDGE, Massachusetts, July 3 /PRNewswire/ --

Alexza's Corporate Presentation to be Webcast at the Piper Jaffray Third Annual Europe Conference
20th June 2008 MOUNTAIN VIEW, California, June 20 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that its corporate presentation will be webcast live during the Piper Jaffray...

Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics
3rd June 2008 SAN DIEGO, June 3 /PRNewswire/ -- Gen-Probe Incorporated (Nasdaq: GPRO), a pioneer and leader in nucleic acid diagnostics for human disease, announced today that it has launched a conditional tender...

Isotechnika to Hold Conference Call to Discuss Positive PROMISE Trial
3rd June 2008 EDMONTON, Canada, June 3 /PRNewswire/ -- Isotechnika Inc. will hold a conference call to discuss final Phase 2b PROMISE kidney transplant data for the Company's lead immunosuppressive...

Genmab Announces 2008 First Quarter Results
28th May 2008 COPENHAGEN, May 28 /PRNewswire/ -- Genmab A/S (OMX: GEN) announced today results for the three month period ended March 31, 2008. During this period, Genmab reported the following results: ...

Rosetta Genomics Reports First Quarter 2008 Financial Results
21st May 2008 REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, May 21 /PRNewswire/ --

Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
14th May 2008 REHOVOT, Israel and JERSEY CITY, New Jersey, May 14 /PRNewswire/ -- Rosetta Genomics (Nasdaq: ROSG), today announced it will release first quarter financial results on May 21, 2008, before the...

Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
9th May 2008 ST. DAVID'S, Bermuda, May 9 /PRNewswire/ -- Warner Chilcott Limited (Nasdaq: WCRX) today announced its results for the quarter ended March 31, 2008. Revenue in the quarter ended March 31,...

Oncolytics Biotech Inc. Announces Details of 2008 Annual Shareholder Meeting
5th May 2008 CALGARY, Canada, May 5 /PRNewswire/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that its 2008 Annual and Special Meeting of the Shareholders will be held on Wednesday, May 7,...

Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
25th April 2008 PRINCETON, New Jersey and MILAN, Italy, April 25 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces the results of a 4-week Phase 1 clinical trial evaluating two oral dose levels of R7128 in...

Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
24th April 2008 PRINCETON, New Jersey and MILAN, Italy, April 24 /PRNewswire/ -- -- Two 4-week cohorts will be enrolled to evaluate R7128 1500mg BID in HCV genotypes 2 and 3 prior non-responders and R7128 1000mg BID...

TopoTarget Successfully Buys Back Full Control of Belinostat
22nd April 2008 COPENHAGEN, April 22 /PRNewswire/ -- TopoTarget A/S (OMX: TOPO) today announced that the company has successfully gained full control of belinostat so that global rights are now wholly owned by the...

Torchmark Corporation Reports First Quarter 2008 Results
16th April 2008 MCKINNEY, Texas, April 16 /PRNewswire/ -- Torchmark Corporation (NYSE: TMK) reported today that for the quarter ended March 31, 2008, net income was US$1.29 per share compared with US$1.37 per share...

Genmab Announces Year End 2007 Financial Results
31st March 2008 COPENHAGEN, Denmark, March 31 /PRNewswire/ -- Genmab A/S (OMX: GEN) announced today results for the financial year ended December 31, 2007. Revenues of DKK 530 million (approximately USD 104...

Partnering consultation free of charge
BioNetwork West 2008
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us